With the discovery in the 1950s of iproniazid, the first monoamine oxidase inhibitor (MAOI), the era of drug treatment for depression had begun. As is often the case, chance played a part in its discovery as iproniazid was originally studied as a treatment for tuberculosis. Side effects seen in tuberculosis patients given iproniazid, such as feelings of euphoria, increased appetite, and improved sleep, led researchers to experiment with the drug in patients with depression. The success in relieving patients of depressive symptoms led to iproniazid becoming the first pharmacological treatment of depression.
Unfortunately, iproniazid was found to be “non-selective,” or not specific, in its activity in the body, which led to safety concerns and ultimately its removal from the U.S. market. One important safety concern was termed the “cheese reaction,” so-called because many aged cheeses contain high levels of an amino acid called tyramine that, when combined with iproniazid, led to dangerous increases in heart rate, high blood pressure, and sweating.
Advances in medical research led to a renewed interest in MAOIs because of the discovery of more selective types that had fewer side effects yet maintained their antidepressant action. Today, even though MAOIs continue to be effective in treating depression, their use has declined because of newer antidepressant medications that have fewer side effects and do not have strict dietary restrictions. MAOIs are, however, still a good option for some people when other treatments have failed. The table below lists available MAOIs followed by information on how they work, what conditions they treat, safety, and cost.
| Drug name | Learn more | See SingleCare price |
|---|---|---|
| Azilect | azilect details | |
| Rasagiline | rasagiline-mesylate details | |
| Emsam | emsam details | |
| Marplan | marplan details | |
| Nardil | nardil details | |
| Phenelzine | phenelzine-sulfate details | |
| Parnate | parnate details | |
| Cyclobenzaprine | cyclobenzaprine-hcl details | |
| Xadago | xadago details |
MAOIs are a class of drugs different from other antidepressants. They’re used for treating depression and other neurologic conditions such as Parkinson’s disease and Alzheimer’s disease. Even though MAOIs were the first drugs discovered for treating depression, they are no longer considered first-line due to safety issues and the introduction of newer, safer classes of drugs such as serotonin antagonist and reuptake inhibitors (SARIs), selective serotonin reuptake inhibitors (SSRIs), and serotonin-norepinephrine reuptake inhibitors (SNRIs). MAOIs are typically prescribed for depression only when other classes of antidepressants are not effective.
The monoamine oxidase enzyme is naturally present in the body. It breaks down—or inactivates—certain neurotransmitters (including serotonin, dopamine, epinephrine, and norepinephrine) known collectively as monoamines. It is believed that patients with depression have decreased amounts of these neurotransmitters in the brain. MAOIs work by inhibiting monoamine oxidase, which, in turn, prevents the breakdown of monoamines and increases the levels of the neurotransmitters in the brain.
MAOIs are primarily used to treat depression but may also used be used to treat the following conditions:
Parkinson’s disease
Despite their potentially serious side effects, MAOIs have been proven effective in treating depression in adults. They’re used less frequently than other antidepressants because of dietary precautions and risks of adverse reactions when combined with certain drugs.
Older patients may be at greater risk of adverse reactions when taking MAOIs. In general, dose selection for an older patient should start at the low end of the dosing range, particularly if they have decreased liver, kidney, or cardiac function. Seniors are also more likely to have a secondary disease or be on drug therapy that may impact the effectiveness or safety of an MAOI.
Antidepressants, including MAOIs, have a mandated “boxed warning,” also called a black box warning, from the U.S. Food and Drug Administration (FDA) due to increased risk of suicidality in children, adolescents, and young adults (up to 24 years of age). For most MAOIs, safety, and effectiveness have not been established for pediatric use. When considering the use of an MAOI in a child or adolescent, the prescriber must balance the potential risks with the clinical benefit.
MAOIs carry a boxed warning regarding the risk of increased suicidal thinking and behavior in some younger patients. Patients of all ages who are started on antidepressants should be monitored for signs of suicidal thoughts and behaviors. MAOIs have a second boxed warning regarding a sudden, severe increase in blood pressure that can occur when certain foods or beverages are consumed during treatment.
Before starting an MAOI, patients should be aware of the serious drug-food drug-drug interactions that could cause serotonin syndrome or hypertensive crisis.
Serotonin syndrome is a serious and potentially life-threatening condition in which there is too much serotonin in the body. Symptoms of serotonin syndrome may include high fever, seizures, uneven heartbeat, or passing out. Emergency medical care may be needed if any of these symptoms occur. MAOIs should not be taken in combination with other drugs that can increase serotonin levels. Following is a list of drug classes and medicines that should not be taken with MAOIs due to concerns of serotonin syndrome:
Selective serotonin reuptake inhibitors (SSRIs) such as Prozac (fluoxetine), Zoloft (sertraline), or Paxil (paroxetine)
Serotonin-norepinephrine reuptake inhibitors (SNRIs) such as Effexor (venlafaxine) or Cymbalta (duloxetine)
Tricyclic antidepressants (TCAs) such as Elavil (amitriptyline), Pamelor (nortriptyline), or Tofranil (imipramine)
Atypical antidepressants such as Wellbutrin (bupropion), Ludiomil (maprotiline), Serzone (nefazodone), or Desyrel (trazodone)
Opioids and other pain medicines such as MS Contin (morphine sulfate), OxyContin (oxycodone), Demerol (meperidine), Duragesic (fentanyl), Dilaudid (hydromorphone), Dolophine (methadone), or Ultram (tramadol)
Sympathomimetic drugs
, such as amphetamines, as well as some cold, hay fever, or weight-reducing products that contain dextromethorphan, pseudoephedrine, phenylephrine, or ephedrine
Triptans such as Imitrex (sumatriptan), Maxalt (rizatriptan), or Zomig (zolmitriptan)
Miscellaneous drugs such as Flexeril (cyclobenzaprine), Tegretol (carbamazepine), Buspar (buspirone), lithium, dopamine, reserpine, or St. John’s wort
A severe increase in blood pressure may occur when there are excess levels of tyramine in the body. Tyramine is a naturally occurring amino acid that helps regulate blood pressure and is also commonly found in certain foods. The enzyme monoamine oxidase breaks down excess tyramine. Because MAOIs reduce the action of monoamine oxidase, tyramine levels can build up to dangerous levels in the body. This increase in tyramine can lead to a serious spike in blood pressure that may require emergency treatment. All patients should be warned that the following foods and beverages must be avoided while taking MAOIs and for two weeks after discontinuing their use:
Meat and fish
Pickled herring
Liver
Dry sausage (including Genoa salami, hard salami, pepperoni, and Lebanon bologna)
Any spoiled or improperly stored meat, poultry, and fish
Vegetables
Broad bean pods (fava bean pods)
Sauerkraut
Fruits
Overripe avocados, bananas, raisins, or figs
Dairy products
Aged cheeses
Yogurt
Beverages
Beer and wine
Alcohol-free and reduced-alcohol beer and wine products
Miscellaneous
Yeast extract (including brewer’s yeast in large quantities)
Meat extract
Most soybean products (including soy sauce and tofu)
Excessive amounts of chocolate and caffeine
Over-the-counter supplements containing tyramine
There are no current MAOI recalls as of April 2021.
MAOIs should be used with caution, or not at all, for those with the following conditions:
A history of mania associated with bipolar disorder
Epilepsy (unless the epilepsy is well controlled)
Pheochromocytoma (a tumor of the adrenal glands)
Serious kidney, liver, or heart problems
There are no adequate and well-controlled studies regarding the use of MAOIs in pregnant women. A decision to use MAOIs during pregnancy is based on the balance between risk and benefit. Likewise, it is unknown if MAOI drugs are present in human milk or what the effect may be on the nursing infant. A woman’s healthcare provider is the best source of information when managing antidepressant treatment when pregnant or breastfeeding.
Never stop an antidepressant medicine without first talking to a healthcare provider. Missing several doses of an MAOI in a row or stopping treatment abruptly may cause withdrawal-like symptoms, including the following:
A general feeling of uneasiness
Restlessness
Anxiety
Depression
Confusion
Hallucinations
Headache
Weakness
Diarrhea
Nausea
Dizziness
Lethargy
Whenever possible, gradually reduce the dose rather than abruptly stopping the medication. If intolerable symptoms occur following a decrease in the dose or upon discontinuation of treatment, then resuming the previously prescribed dose may be considered. The healthcare provider may continue decreasing the dose but at a more gradual rate.
No, MAOIs are not controlled substances.
The following are potential common side effects of MAOIs. This is not an exhaustive list and you should always consult a healthcare professional for professional medical advice before taking MAOIs.
Orthostatic hypotension (temporary lowering of blood pressure, usually related to suddenly standing up)
Dizziness
Headache
Insomnia
Restlessness
CNS stimulation
Muscle spasms
Tremor
Myoclonic jerks (sudden muscle contraction)
Anxiety
Agitation
Weakness
Blurred vision
Nausea
Vomiting
Drowsiness
Loss of appetite
Palpitations
Tachycardia
Ejaculatory dysfunction
Impotence
Dry mouth
Swelling of lower legs or hands
Diarrhea
Constipation
Paresthesia (tingling or prickly sensation in hands or feet)
Tinnitus (ringing or buzzing in the ears)
Urinary retention
Rash
RELATED: Going on antidepressants: A beginner’s guide to side effects
MAOIs have a wide price range depending on the specific drug, quantity, and dosage. Since several MAOIs are available in generic form, they are much less than the brand-name counterpart. For example, generic tranylcypromine costs about $661 for 120, 10 mg tablets. The brand-name version, Parnate, could cost more than $1,000 for the same strength and quantity. You can compare costs of generic vs. brand-name drugs on singlecare.com, and use a free SingleCare card to reduce certain prescription costs up to 80% at participating pharmacies.
Keith Gardner, R.Ph., is a graduate of Southwestern Oklahoma State University School of Pharmacy. He has 10 years of community pharmacy experience followed by a 22-year career with a major pharmaceutical company in which he served as a medical information consultant. In that role, Gardner provided medical information to consumers and healthcare providers in numerous disease states. He currently resides in Monument, Colorado, with his wife and three dogs.
...Health education, drug info, wellness & more
Prescription savings vary by prescription and by pharmacy, and may reach up to 80% off cash price. This is a medical discount plan. This is NOT insurance. This program offers you the opportunity to locate providers of various types of medical services who will offer their services to you at discounted rates. The range of discounts for medical or ancillary services provided under the plan will vary depending on the type of provider and service received. You are fully responsible for paying for all health care services but will be entitled to receive a discount from those health care providers in accordance with the specific pre-negotiated discounted fee schedule. This program does not guarantee the quality of the services or procedures offered by the providers. Except for prescription drugs which you will pay directly to the pharmacy at the time of purchase, all other services received through a program provider will be charged to the credit card on file in your member account. The charge will include an administrative fee for use of the program. Towers Administrators LLC is the licensed discount medical plan organization with its administrative office located at 4510 Cox Road, Suite 111, Glen Allen, VA 23060. SingleCare Services, LLC is the marketer of the discount medical plan organization including its website, singlecare.com, with its corporate office located at 99 High Street, Suite 2800, Boston, MA 02110. For additional information, including an up-to-date list of providers, or assistance with any issue related to program membership, please contact member support any time at www.singlecare.com, or by calling toll-free 844-234-3057, 24 hours, 7 days a week (except major holidays). Pharmacy names, logos, brands, and other trademarks are the property of their respective owners.
Blog articles are not medical advice. They are intended for general informational purposes and are not meant to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. If you think you may have a medical emergency, immediately call your physician or dial 911.
© 2025 SingleCare Administrators. All rights reserved
© 2025 SingleCare Administrators. All rights reserved